'Reference composition' not 'lead compound': recent developments in case law for obviousness of pharmaceutical composition claims
{{output}}
For most chemical compound claims, the obviousness analysis begins with the identification of a 'lead compound'. Pursuant to a recent decision from the Federal Circuit, a similar framework is now applicable for pharmaceutical composition claims. In Unigene Lab... ...
